25/01/2012
- The three-year integrated drug discovery alliance
is for identifying drug development candidates
-
Collaboration is for treating respiratory
disease
- The value of this collaboration could reach € 7.5 million
Barcelona (Spain) and Mechelen (Belgium), 25 January 2012.- Almirall, S.A. (ALM.MC) announced today that has formed a research alliance with BioFocus, an affiliate from Galapagos NV (Euronext: GLPG).
The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort. The value of this collaboration to BioFocus could reach €7.5 million.
"We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies" said Dr. Bertil Lindmark, CSO, Executive Director R&D of Almirall.
"We are delighted to form a drug discovery alliance with one of Europe's leading research-based pharmaceutical companies" added Dr. Chris Newton, SVP Galápagos Services and Managing Director, BioFocus.
Respiratory is a key research focus for Almirall together with gastrointestinal and dermatology areas where the company is especially engaged to offer new therapeutic solutions.
About Almirall
Almirall is an international pharmaceutical company based
on innovation and committed to health. Headquartered in
Barcelona, Spain, it researches, develops, manufactures and
commercialises its own R&D and licensed drugs with the aim
of improving people's health and
wellbeing.
Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions.
Almirall's products are currently present in over 70 countries while it has direct presence in Europeand Latin Americathrough 12 affiliates.
For further information please visit the website at:
About BioFocus
BioFocus provides integrated drug discovery that delivers
pre-clinical drug candidates in all therapeutic areas with
strong capability in neurodegenerative diseases,
inflammatory diseases and with a growing track record of
delivering candidates against rare and neglected diseases.
BioFocus has advanced and comprehensive drug discovery
capabilities that are applied to client projects to deliver
targets, hits, leads and candidate pre-clinical
drugs. The company employs over 220 exceptionally
qualified and industry experienced scientists at its three
research centers in the UK, Switzerlandand the
Netherlands.
Since its foundation in 1997, BioFocus has striven to produce high quality data for its clients and this quality is assured by ISO9001 qualification validated by regular, independent inspection of all BioFocus research centers. For more information visit:
(Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology
company specialized in the discovery and development of
small molecule and antibody therapies with novel
modes-of-action. The Company is progressing one of
the largest pipelines in biotech, with seven programs in
development and over 50 discovery programs. Through
risk/reward-sharing alliances with GlaxoSmithKline, Lilly,
Janssen Pharmaceutica, Roche and Servier, Galapagos is
eligible to receive up to €2.8 billion in downstream
milestones, plus royalties. The Galapagos Group has
about 800 employees and operates facilities in six
countries, with global headquarters in Mechelen,
Belgium. More info at:
More information:
Ketchum Pleon
Sonia San Segundo
sonia.sansegundo@ketchumpleon.com
Tel.: 91 788 32 00
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
distribué par | Ce noodl a été diffusé par Almirall SA et initialement mise en ligne sur le site http://www.almirall.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-25 11:42:17 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |